Product Code: PMRREP33292
Vaginal Antifungals Market - Report Scope
A recent market study published by Persistence Market Research on the vaginal antifungals market offers a global industry analysis for 2017 to 2021 and an opportunity assessment for 2022 to 2032. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the vaginal antifungals market, growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the vaginal antifungals market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.
The report provides detailed information about the current and future growth prospects of the vaginal antifungals market in the most comprehensive way for a better understanding of readers.
Key Market Segments
The study on the vaginal antifungals market offers insights divided into four important segments - drug, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug
Fluconazole
Nystatin
Flucytosine
Clotrimazole
Ketoconazole
Terbinafine
Others
Route of Administration
Oral
Topical
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa
Chapter 1 - Executive Summary
- The report commences with the executive summary of the vaginal antifungals market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the vaginal antifungals market as well as the key trends influencing the market.
Chapter 2 - Market Overview
- Readers can find detailed taxonomy and drug definition/scope /limitations and inclusions and exclusions of the vaginal antifungals market in this chapter, which helps the readers to understand basic information about the vaginal antifungals market.
Chapter 3 - Key Market Trends
- This section highlights the key trends influencing the vaginal antifungals market, which will help readers in understanding the current trends and their impact on market growth.
Chapter 4 - Key Success Factors
- This section highlights the market context impacting the vaginal antifungals market, which will help readers in understanding promotional strategies, by key manufacturers, key regulations, reimbursement scenario, pipeline analysis, value chain analysis, PESTEL analysis, and Porter's analysis, that are expected to create a positive impact on the growth of the vaginal antifungals market during the forecast period.
Chapter 5- Market Background
- This chapter explains the key macroeconomic factors that are expected to influence the growth of the vaginal antifungals market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the vaginal antifungals market, which include the drivers, restraints, and opportunity analysis.
Chapter 6 - COVID-19 Crisis Analysis
- This section provides the current and expected impact of COVID-19 on the vaginal antifungals market.
Chapter 7- Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
- This section explains the global market value or size analysis and forecasts for the vaginal antifungals market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2022), and an incremental $ opportunity for the forecast period (2022-2032).
Chapter 8- Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, by Drug
- Based on the drug, the vaginal antifungals market is segmented into Fluconazole, Nystatin, Flucytosine, Clotrimazole, Ketoconazole, Terbinafine, and others. In this chapter, readers can find information about a detailed analysis of the market by different drugs available in the vaginal antifungals market and their growth over the forecast period.
Chapter 9- Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
- Based on the route of administration, the vaginal antifungals market is segmented into oral, and topical. In this chapter, readers can find information about a detailed analysis of the market by various routes of administration available in the vaginal antifungals market and their growth over the forecast period.
Chapter 10- Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
- Based on the distribution channel, the vaginal antifungals market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In this chapter, readers can find information about a detailed analysis of the market by distribution channels available in the vaginal antifungals market and their growth over the forecast period.
Chapter 11 - Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, by Region
- This chapter explains how the vaginal antifungals market will grow across seven geographic regions, North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa (MEA).
Chapter 12- North America Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- This chapter includes a detailed analysis of the growth of the North American vaginal antifungals market along with a country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on drug, distribution channel, route of administration, and country of the vaginal antifungals market in the North American region.
Chapter 13- Latin America Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- This chapter includes the growth prospects of the vaginal antifungals market in leading countries such as Brazil, Mexico, Argentina, and the rest of Latin America. Readers can find thorough information about the growth parameters based on drug, distribution channel, route of administration, and country in the Latin America vaginal antifungals market during 2022-2032.
Chapter 14- Europe Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- This chapter includes the growth prospects of the vaginal antifungals market based on the development of the new product, regulatory approvals, and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, BENELUX, and the Rest of Europe are included in this chapter.
Chapter 15- East Asia Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- China, Japan, and South Korea are the prime subjects of assessment to obtain the growth prospects of the East Asia vaginal antifungals market. In addition, in this chapter, readers can find thorough information about the growth parameters of the East Asia vaginal antifungals market through 2032.
Chapter 16- South Asia Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- India, Thailand, Indonesia, Malaysia, and the rest of South Asia are the prime subjects of assessment to obtain the growth prospects of the vaginal antifungals market. In addition, in this chapter, readers can find thorough information about the growth parameters of the South Asia vaginal antifungals market growth over the forecast period.
Chapter 17- Oceania Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- This chapter consists of important parameters that have a huge impact on the growth of the vaginal antifungals market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania vaginal antifungals market.
Chapter 18- Middle East and Africa Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- This chapter provides information on how the vaginal antifungals market will grow in the major countries in the MEA region, such as GCC Countries, Turkiye, and the rest of MEA during 2022-2032.
Chapter 19- Market Structure Analysis
- This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key players operating in the vaginal antifungals market.
Chapter 20- Competition Analysis
- In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the vaginal antifungals market including company overview, revenue shares, strategic overview, and recent company developments. Some of the major market players featured in the report are Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, SCYNEXIS, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., and Amplyx Pharmaceuticals Inc.
Chapter 21 - Assumptions and Acronyms Used
- This chapter includes a list of acronyms and assumptions that provide a base for the information and statistics included in the report.
Chapter 22 - Research Methodology
- This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the vaginal antifungals market.
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions and Exclusions
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Key Innovation / Development Trends
4. Key Success Factors
- 4.1. Promotional Strategies, By Key Manufacturers
- 4.2. Key Regulations
- 4.3. Reimbursement Scenario
- 4.4. Pipeline Analysis
- 4.5. Value Chain Analysis
- 4.6. PESTEL Analysis
- 4.7. Porter's Analysis
5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Expenditure Outlook
- 5.1.3. Global Antifungal Drugs Market Outlook
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Impact of the COVID-19 Pandemic
- 5.2.2. Increasing Product Launch Activities
- 5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
- 5.2.4. High Rates of Vulvovaginal Candidiasis
- 5.2.5. Impact on Quality-of-Life
- 5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
- 5.2.7. Growing Problems of Azole Resistance
- 5.2.8. Toxicity of Antifungal Drugs
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
- 6.1. COVID-19 and Impact Analysis
- 6.1.1. By Drug
- 6.1.2. By Route of Administration
- 6.1.3. By Distribution Channel
- 6.1.4. By Country
- 6.2. 2021 Market Scenario
7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
- 7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Drug
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2017 - 2021
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2022 - 2032
- 8.3.1. Fluconazole
- 8.3.2. Nystatin
- 8.3.3. Flucytosine
- 8.3.4. Clotrimazole
- 8.3.5. Ketoconazole
- 8.3.6. Terbinafine
- 8.3.7. Others
- 8.4. Market Attractiveness Analysis By Drug
9. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2017 - 2021
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022 - 2032
- 9.3.1. Oral
- 9.3.2. Topical
- 9.4. Market Attractiveness Analysis By Route of Administration
10. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017 - 2021
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 - 2032
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Region
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
- 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa
- 11.4. Market Attractiveness Analysis By Region
12. North America Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 12.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 12.3.1. By Country
- 12.3.1.1. U.S.
- 12.3.1.2. Canada
- 12.3.2. By Drug
- 12.3.3. By Route of Administration
- 12.3.4. By Distribution Channel
- 12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Drug
- 12.4.3. By Route of Administration
- 12.4.4. By Distribution Channel
- 12.5. Market Trends
- 12.6. Key Market Participants - Intensity Mapping
- 12.7. Drivers and Restraints - Impact Analysis
- 12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Vaginal Antifungals Market Analysis
- 12.8.1.1. Introduction
- 12.8.1.2. Market Analysis and Forecast By Market Taxonomy
- 12.8.1.2.1. By Drug
- 12.8.1.2.2. By Route of Administration
- 12.8.1.2.3. By Distribution Channel
- 12.8.2. Canada Vaginal Antifungals Market Analysis
- 12.8.2.1. Introduction
- 12.8.2.2. Market Analysis and Forecast By Market Taxonomy
- 12.8.2.2.1. By Drug
- 12.8.2.2.2. By Route of Administration
- 12.8.2.2.3. By Distribution Channel
13. Latin America Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 13.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 13.3.1. By Country
- 13.3.1.1. Mexico
- 13.3.1.2. Brazil
- 13.3.1.3. Argentina
- 13.3.1.4. Rest of Latin America
- 13.3.1.4.1. By Country
- 13.3.1.4.2. By Drug
- 13.3.1.4.3. By Route of Administration
- 13.3.1.4.4. By Distribution Channel
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug
- 13.4.3. By Route of Administration
- 13.4.4. By Distribution Channel
- 13.5. Market Trends
- 13.6. Key Market Participants - Intensity Mapping
- 13.7. Drivers and Restraints - Impact Analysis
- 13.8. Country Level Analysis & Forecast
- 13.8.1. Mexico Vaginal Antifungals Market Analysis
- 13.8.1.1. Introduction
- 13.8.1.2. Market Analysis and Forecast By Market Taxonomy
- 13.8.1.2.1. By Drug
- 13.8.1.2.2. By Route of Administration
- 13.8.1.2.3. By Distribution Channel
- 13.8.2. Brazil Vaginal Antifungals Market Analysis
- 13.8.2.1. Introduction
- 13.8.2.2. Market Analysis and Forecast By Market Taxonomy
- 13.8.2.2.1. By Country
- 13.8.2.2.2. By Drug
- 13.8.2.2.3. By Route of Administration
- 13.8.2.2.4. By Distribution Channel
- 13.8.3. Argentina Vaginal Antifungals Market Analysis
- 13.8.3.1. Introduction
- 13.8.3.2. Market Analysis and Forecast By Market Taxonomy
- 13.8.3.2.1. By Drug
- 13.8.3.2.2. By Route of Administration
- 13.8.3.2.3. By Distribution Channel
14. Europe Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 14.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 14.3.1. By Country
- 14.3.1.1. Germany
- 14.3.1.2. Italy
- 14.3.1.3. France
- 14.3.1.4. U.K.
- 14.3.1.5. Spain
- 14.3.1.6. BENELUX
- 14.3.1.7. Russia
- 14.3.1.8. Rest of Europe
- 14.3.2. By Drug
- 14.3.3. By Route of Administration
- 14.3.4. By Distribution Channel
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug
- 14.4.3. By Route of Administration
- 14.4.4. By Distribution Channel
- 14.5. Market Trends
- 14.6. Key Market Participants - Intensity Mapping
- 14.7. Drivers and Restraints - Impact Analysis
- 14.8. Country Level Analysis & Forecast
- 14.8.1. Germany Vaginal Antifungals Market Analysis
- 14.8.1.1. Introduction
- 14.8.1.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.1.2.1. By Drug
- 14.8.1.2.2. By Route of Administration
- 14.8.1.2.3. By Distribution Channel
- 14.8.2. Italy Vaginal Antifungals Market Analysis
- 14.8.2.1. Introduction
- 14.8.2.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.2.2.1. By Drug
- 14.8.2.2.2. By Route of Administration
- 14.8.2.2.3. By Distribution Channel
- 14.8.3. France Vaginal Antifungals Market Analysis
- 14.8.3.1. Introduction
- 14.8.3.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.3.2.1. By Drug
- 14.8.3.2.2. By Route of Administration
- 14.8.3.2.3. By Distribution Channel
- 14.8.4. U.K. Vaginal Antifungals Market Analysis
- 14.8.4.1. Introduction
- 14.8.4.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.4.2.1. By Drug
- 14.8.4.2.2. By Route of Administration
- 14.8.4.2.3. By Distribution Channel
- 14.8.5. Spain Vaginal Antifungals Market Analysis
- 14.8.5.1. Introduction
- 14.8.5.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.5.2.1. By Drug
- 14.8.5.2.2. By Route of Administration
- 14.8.5.2.3. By Distribution Channel
- 14.8.6. BENELUX Vaginal Antifungals Market Analysis
- 14.8.6.1. Introduction
- 14.8.6.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.6.2.1. By Drug
- 14.8.6.2.2. By Route of Administration
- 14.8.6.2.3. By Distribution Channel
- 14.8.7. Russia Vaginal Antifungals Market Analysis
- 14.8.7.1. Introduction
- 14.8.7.2. Market Analysis and Forecast By Market Taxonomy
- 14.8.7.2.1. By Drug
- 14.8.7.2.2. By Route of Administration
- 14.8.7.2.3. By Distribution Channel
15. East Asia Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 15.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 15.3.1. By Country
- 15.3.1.1. China
- 15.3.1.2. Japan
- 15.3.1.3. South Korea
- 15.3.2. By Drug
- 15.3.3. By Route of Administration
- 15.3.4. By Distribution Channel
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug
- 15.4.3. By Route of Administration
- 15.4.4. By Distribution Channel
- 15.5. Market Trends
- 15.6. Key Market Participants - Intensity Mapping
- 15.7. Drivers and Restraints - Impact Analysis
- 15.8. Country Level Analysis & Forecast
- 15.8.1. China Vaginal Antifungals Market Analysis
- 15.8.1.1. Introduction
- 15.8.1.2. Market Analysis and Forecast By Market Taxonomy
- 15.8.1.2.1. By Drug
- 15.8.1.2.2. By Route of Administration
- 15.8.1.2.3. By Distribution Channel
- 15.8.2. Japan Vaginal Antifungals Market Analysis
- 15.8.2.1. Introduction
- 15.8.2.2. Market Analysis and Forecast By Market Taxonomy
- 15.8.2.2.1. By Drug
- 15.8.2.2.2. By Route of Administration
- 15.8.2.2.3. By Distribution Channel
- 15.8.3. South Korea Vaginal Antifungals Market Analysis
- 15.8.3.1. Introduction
- 15.8.3.2. Market Analysis and Forecast By Market Taxonomy
- 15.8.3.2.1. By Drug
- 15.8.3.2.2. By Route of Administration
- 15.8.3.2.3. By Distribution Channel
16. South Asia Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 16.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 16.3.1. By Country
- 16.3.1.1. India
- 16.3.1.2. Indonesia
- 16.3.1.3. Malaysia
- 16.3.1.4. Thailand
- 16.3.1.5. Rest of South Asia
- 16.3.2. By Drug
- 16.3.3. By Route of Administration
- 16.3.4. By Distribution Channel
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug
- 16.4.3. By Route of Administration
- 16.4.4. By Distribution Channel
- 16.5. Market Trends
- 16.6. Key Market Participants - Intensity Mapping
- 16.7. Drivers and Restraints - Impact Analysis
- 16.8. Country Level Analysis & Forecast
- 16.8.1. India Vaginal Antifungals Market Analysis
- 16.8.1.1. Introduction
- 16.8.1.2. Market Analysis and Forecast By Market Taxonomy
- 16.8.1.2.1. By Drug
- 16.8.1.2.2. By Route of Administration
- 16.8.1.2.3. By Distribution Channel
- 16.8.2. Indonesia Vaginal Antifungals Market Analysis
- 16.8.2.1. Introduction
- 16.8.2.2. Market Analysis and Forecast By Market Taxonomy
- 16.8.2.2.1. By Drug
- 16.8.2.2.2. By Route of Administration
- 16.8.2.2.3. By Distribution Channel
- 16.8.3. Malaysia Vaginal Antifungals Market Analysis
- 16.8.3.1. Introduction
- 16.8.3.2. Market Analysis and Forecast By Market Taxonomy
- 16.8.3.2.1. By Drug
- 16.8.3.2.2. By Route of Administration
- 16.8.3.2.3. By Distribution Channel
- 16.8.4. Thailand Vaginal Antifungals Market Analysis
- 16.8.4.1. Introduction
- 16.8.4.2. Market Analysis and Forecast By Market Taxonomy
- 16.8.4.2.1. By Drug
- 16.8.4.2.2. By Route of Administration
- 16.8.4.2.3. By Distribution Channel
17. Oceania Vaginal Antifungals Market 2017-2021 and Forecast 2022-2032
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 17.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 17.3.1. By Country
- 17.3.1.1. Australia
- 17.3.1.2. New Zealand
- 17.3.2. By Drug
- 17.3.3. By Route of Administration
- 17.3.4. By Distribution Channel
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug
- 17.4.3. By Route of Administration
- 17.4.4. By Distribution Channel
- 17.5. Key Market Participants - Intensity Mapping
- 17.6. Drivers and Restraints - Impact Analysis
- 17.7. Country Level Analysis & Forecast
- 17.7.1. Australia Vaginal Antifungals Market Analysis
- 17.7.1.1. Introduction
- 17.7.1.2. Market Analysis and Forecast By Market Taxonomy
- 17.7.1.2.1. By Drug
- 17.7.1.2.2. By Route of Administration
- 17.7.1.2.3. By Distribution Channel
- 17.7.2. New Zealand Vaginal Antifungals Market Analysis
- 17.7.2.1. Introduction
- 17.7.2.2. Market Analysis and Forecast By Market Taxonomy
- 17.7.2.2.1. By Drug
- 17.7.2.2.2. By Route of Administration
- 17.7.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 18.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022-2032
- 18.3.1. By Country
- 18.3.1.1. GCC Countries
- 18.3.1.2. Turkiye
- 18.3.1.3. South Africa
- 18.3.1.4. North Africa
- 18.3.1.5. Rest of Middle East and Africa
- 18.3.2. By Drug
- 18.3.3. By Route of Administration
- 18.3.4. By Distribution Channel
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug
- 18.4.3. By Route of Administration
- 18.4.4. By Distribution Channel
- 18.5. Market Trends
- 18.6. Key Market Participants - Intensity Mapping
- 18.7. Drivers and Restraints - Impact Analysis
- 18.8. Country Level Analysis & Forecast
- 18.8.1. GCC Countries Vaginal Antifungals Market Analysis
- 18.8.1.1. Introduction
- 18.8.1.2. Market Analysis and Forecast By Market Taxonomy
- 18.8.1.2.1. By Drug
- 18.8.1.2.2. By Route of Administration
- 18.8.1.2.3. By Distribution Channel
- 18.8.2. Turkiye Vaginal Antifungals Market Analysis
- 18.8.2.1. Introduction
- 18.8.2.2. Market Analysis and Forecast By Market Taxonomy
- 18.8.2.2.1. By Drug
- 18.8.2.2.2. By Route of Administration
- 18.8.2.2.3. By Distribution Channel
- 18.8.3. South Africa Vaginal Antifungals Market Analysis
- 18.8.3.1. Introduction
- 18.8.3.2. Market Analysis and Forecast By Market Taxonomy
- 18.8.3.2.1. By Drug
- 18.8.3.2.2. By Route of Administration
- 18.8.3.2.3. By Distribution Channel
- 18.8.4. North Africa Vaginal Antifungals Market Analysis
- 18.8.4.1. Introduction
- 18.8.4.2. Market Analysis and Forecast By Market Taxonomy
- 18.8.4.2.1. By Drug
- 18.8.4.2.2. By Route of Administration
- 18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
- 19.1. Market Analysis By Tier of Companies
- 19.2. Market Concentration
- 19.3. Market Share Analysis of Top Players
- 19.4. Market Presence Analysis
20. Competition Analysis
- 20.1. Competition Dashboard
- 20.2. Competition Benchmarking
- 20.3. Competition Deep Dive
- 20.3.1. Pfizer Inc.
- 20.3.1.1. Overview
- 20.3.1.2. Product Portfolio
- 20.3.1.3. Sales Footprint
- 20.3.1.4. Key Financials
- 20.3.1.5. SWOT Analysis
- 20.3.1.6. Strategic Overview
- 20.3.2. Bausch Health Companies Inc
- 20.3.2.1. Overview
- 20.3.2.2. Product Portfolio
- 20.3.2.3. Sales Footprint
- 20.3.2.4. Key Financials
- 20.3.2.5. SWOT Analysis
- 20.3.2.6. Strategic Overview
- 20.3.3. ANI Pharmaceuticals, Inc.
- 20.3.3.1. Overview
- 20.3.3.2. Product Portfolio
- 20.3.3.3. Sales Footprint
- 20.3.3.4. Key Financials
- 20.3.3.5. SWOT Analysis
- 20.3.3.6. Strategic Overview
- 20.3.4. Hikma Pharmaceuticals Plc
- 20.3.4.1. Overview
- 20.3.4.2. Product Portfolio
- 20.3.4.3. Sales Footprint
- 20.3.4.4. Key Financials
- 20.3.4.5. SWOT Analysis
- 20.3.4.6. Strategic Overview
- 20.3.5. Lupin Limited
- 20.3.5.1. Overview
- 20.3.5.2. Product Portfolio
- 20.3.5.3. Sales Footprint
- 20.3.5.4. Key Financials
- 20.3.5.5. SWOT Analysis
- 20.3.5.6. Strategic Overview
- 20.3.6. Mycovia Pharmaceuticals, Inc.
- 20.3.6.1. Overview
- 20.3.6.2. Product Portfolio
- 20.3.6.3. Sales Footprint
- 20.3.6.4. Key Financials
- 20.3.6.5. SWOT Analysis
- 20.3.6.6. Strategic Overview
- 20.3.7. Glenmark Pharmaceuticals Limited
- 20.3.7.1. Overview
- 20.3.7.2. Product Portfolio
- 20.3.7.3. Sales Footprint
- 20.3.7.4. Key Financials
- 20.3.7.5. SWOT Analysis
- 20.3.7.6. Strategic Overview
- 20.3.8. Unique Pharmaceuticals
- 20.3.8.1. Overview
- 20.3.8.2. Product Portfolio
- 20.3.8.3. Sales Footprint
- 20.3.8.4. Key Financials
- 20.3.8.5. SWOT Analysis
- 20.3.8.6. Strategic Overview
- 20.3.9. PEPTONIC medical AB
- 20.3.9.1. Overview
- 20.3.9.2. Product Portfolio
- 20.3.9.3. Sales Footprint
- 20.3.9.4. Key Financials
- 20.3.9.5. SWOT Analysis
- 20.3.9.6. Strategic Overview
- 20.3.10. Aurobindo Pharma Limited
- 20.3.10.1. Overview
- 20.3.10.2. Product Portfolio
- 20.3.10.3. Sales Footprint
- 20.3.10.4. Key Financials
- 20.3.10.5. SWOT Analysis
- 20.3.10.6. Strategic Overview
- 20.3.11. Dr. Reddy's Laboratories
- 20.3.11.1. Overview
- 20.3.11.2. Product Portfolio
- 20.3.11.3. Sales Footprint
- 20.3.11.4. Key Financials
- 20.3.11.5. SWOT Analysis
- 20.3.11.6. Strategic Overview
- 20.3.12. SCYNEXIS, Inc.
- 20.3.12.1. Overview
- 20.3.12.2. Product Portfolio
- 20.3.12.3. Sales Footprint
- 20.3.12.4. Key Financials
- 20.3.12.5. SWOT Analysis
- 20.3.12.6. Strategic Overview
- 20.3.13. Basilea Pharmaceutica Ltd.
- 20.3.13.1. Overview
- 20.3.13.2. Product Portfolio
- 20.3.13.3. Sales Footprint
- 20.3.13.4. Key Financials
- 20.3.13.5. SWOT Analysis
- 20.3.13.6. Strategic Overview
- 20.3.14. Astellas Pharma Inc.
- 20.3.14.1. Overview
- 20.3.14.2. Product Portfolio
- 20.3.14.3. Sales Footprint
- 20.3.14.4. Key Financials
- 20.3.14.5. SWOT Analysis
- 20.3.14.6. Strategic Overview
- 20.3.15. Grupo Ferrer Internacional, S.A.
- 20.3.15.1. Overview
- 20.3.15.2. Product Portfolio
- 20.3.15.3. Sales Footprint
- 20.3.15.4. Key Financials
- 20.3.15.5. SWOT Analysis
- 20.3.15.6. Strategic Overview
- 20.3.16. Pacgen Life Science Corporation
- 20.3.16.1. Overview
- 20.3.16.2. Product Portfolio
- 20.3.16.3. Sales Footprint
- 20.3.16.4. Key Financials
- 20.3.16.5. SWOT Analysis
- 20.3.16.6. Strategic Overview
- 20.3.17. NovaDigm Therapeutics, Inc.
- 20.3.17.1. Overview
- 20.3.17.2. Product Portfolio
- 20.3.17.3. Sales Footprint
- 20.3.17.4. Key Financials
- 20.3.17.5. SWOT Analysis
- 20.3.17.6. Strategic Overview
- 20.3.18. Cidara Therapeutics, Inc.
- 20.3.18.1. Overview
- 20.3.18.2. Product Portfolio
- 20.3.18.3. Sales Footprint
- 20.3.18.4. Key Financials
- 20.3.18.5. SWOT Analysis
- 20.3.18.6. Strategic Overview
- 20.3.19. Amplyx Pharmaceuticals Inc.
- 20.3.19.1. Overview
- 20.3.19.2. Product Portfolio
- 20.3.19.3. Sales Footprint
- 20.3.19.4. Key Financials
- 20.3.19.5. SWOT Analysis
- 20.3.19.6. Strategic Overview
21. Assumptions and Acronyms Used
22. Research Methodology